First healthy volunteers dosed on schedule
Evgen Pharma PLC (AIM:EVG) SFX-01 licensing deal for up to $160.5m
SFX-01 licensing deal for up to $160.5m in milestone payments expands lead asset into neurodevelopmental disorders
Evgen Pharma PLC (EVG.L) Progress with UK and US regulators for 2022 trials
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of cancers and inflammation, announces that it has progressed discussions with the
Evgen Pharma PLC (EVG.L) Publication of data in glioblastoma cells
Publication shows effectiveness of SFX-01 in patient derived glioblastoma cells University of Auckland data
Evgen Pharma PLC (EVG.L) Early data for SFX-01 in leukaemia cell lines
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces preclinical data demonstrating that SFX-01 was effective in
Overview facts about hVIVO COVID Clear & FAQ
Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical